Inaguma S, Lasota J, Czapiewski P, et al. - In this study, 172 well-characterized primary diffuse mesothelioma of the pleura (MPM) tumors—including epithelioid (n = 145), biphasic (n = 15), and sarcomatoid (n = 12) histotypes—were assessed immunohistochemically for CD70, CD27, CD3, CD4, CD8, CD56, PDCD1 (PD-1), and FOXP3 expression. The investigators noted that in people with these neoplasms, the CD70–CD27 pathway enhanced the malignant phenotypes of MPM, and reduced anti-tumor immune response. Moreover, these markers might be beneficial in MPM for prognostic assessments as well as targeted therapeutics.